John Mavrianos

Associate Scientist V at Alexion Pharmaceuticals (AstraZeneca Rare Disease)

Speaker

John Mavrianos is an Associate scientist V in the upstream department for Alexion Pharmaceuticals AstraZeneca Rare Disease. He is responsible for leading and executing laboratory efforts for process development to support pre-clinical, early, and late phase biopharmaceutical programs. John is considered to be a technical subject matter expert in multiple units of operation ranging from small scale high throughput bioreactors to 20,000 L GMP production bioreactors. John also has experience in late-stage technical transfer that is reenforced by his expertise and comprehensive scientific knowledge in the scale-up of biological therapeutic protein manufacturing. In his current role John and his team are leveraging newly accessible AstraZeneca proprietary media and feeds to significantly improve yields of a commercially approved protein, enabling cost reduction, and providing access to patients in emerging markets.
John has over two decades of experience in drug development and commercial GMP manufacturing and holds a bachelor’s degree of science from Rutgers University New Brunswick, New Jersey.